organization · Reporting owner
Strathspey Crown Holdings Group, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AEON Biopharma, Inc.
Report date August 11, 2023 · Filed August 14, 2023
Section 16 reporting ended · disclosed 2023-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,031,773 |
Reported balance
After 2023-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-11 · Sale · Disposed 7,380,394 · Balance 2,031,773 F1: Reflects the disposition of shares of the Issuer's Class A Common Stock (the "Distributed Shares") by the Reporting Person in connection with the repurchase of certain of the Reporting Person's membership interests held by its members in exchange for, among other consideration, the Distributed Shares. F2: In addition to the disposition of the Distributed Shares, the amount reflected includes a reduction in the Reporting Person's beneficial ownership by an additional 8,203 shares of the Issuer's Class A Common Stock to correct an inadvertent overstatement of such ownership by such amount in the Reporting Person's Form 3 filed with the Securities and Exchange Commission on July 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of the Issuer's Class A Common Stock (the "Distributed Shares") by the Reporting Person in connection with the repurchase of certain of the Reporting Person's membership interests held by its members in exchange for, among other consideration, the Distributed Shares.
F2: In addition to the disposition of the Distributed Shares, the amount reflected includes a reduction in the Reporting Person's beneficial ownership by an additional 8,203 shares of the Issuer's Class A Common Stock to correct an inadvertent overstatement of such ownership by such amount in the Reporting Person's Form 3 filed with the Securities and Exchange Commission on July 31, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2023 Filed Aug 14, 2023 16:10 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | SaleClass A Common Stock | 7,380,394 | $10.00 | $73,803,940.00 |
DisclosureSEC source: 0001477932-23-006094 · form4.xml · nonDerivative · entry 1 Strathspey Crown Holdings Group, LLC · CIK 0001557024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,031,773 F1 · shares: Reflects the disposition of shares of the Issuer's Class A Common Stock (the "Distributed Shares") by the Reporting Person in connection with the repurchase of certain of the Reporting Person's membership interests held by its members in exchange for, among other consideration, the Distributed Shares. F2 · balance_after: In addition to the disposition of the Distributed Shares, the amount reflected includes a reduction in the Reporting Person's beneficial ownership by an additional 8,203 shares of the Issuer's Class A Common Stock to correct an inadvertent overstatement of such ownership by such amount in the Reporting Person's Form 3 filed with the Securities and Exchange Commission on July 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.